A new class of combination therapy within immuno-oncology.
Activated innate immune cells deliver an oncolytic virus.
Intravenous delivery to solid & non-solid tumors.
Safety and toxicity of each component previously tested and established in humans.
Target to effector ratio is 1:1,000,000; allows de-bulking of large tumors.
Multi-mechanistic, so broadly applicable to several indications.
Durable immune response and thus potentially curative.
Copyright © ConcentRx. All rights reserved.